Anika Therapeutics (ANIK) Short term Debt (2010 - 2022)

Anika Therapeutics (ANIK) has reported Short term Debt for 7 consecutive years, with $4.3 million the latest figure, recorded in Q2 2022.

• On a quarterly basis, Short term Debt fell 74.42% year-over-year to $4.3 million in Q2 2022; TTM through Jun 2022 was $4.3 million, a 74.42% decrease from a year earlier, with the FY2021 full-year figure at $4.3 million, down 67.04% from the prior year.
• Short term Debt was $4.3 million for Q2 2022 at Anika Therapeutics, roughly flat from $4.3 million in the prior quarter.
• Over five years, Short term Debt peaked at $24.8 million in Q1 2021 and troughed at $3.5 million in Q3 2021.
• A 3-year average of $10.2 million and a median of $4.3 million in 2021 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt sank 67.04% in 2021 and slumped 82.62% in 2022, its largest moves.
• Over 3 years, Short term Debt stood at $13.1 million in 2020, then slumped by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
• The last three Short term Debt figures came in at $4.3 million (Q2 2022), $4.3 million (Q1 2022), and $4.3 million (Q4 2021), per Business Quant data.